Global landscape analysis of no-fault compensation programmes for vaccine injuries: A review and survey of implementing countries
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
To update the landscape analysis of vaccine injuries no-fault compensation programmes, we conducted a scoping review and a survey of World Health Organization Member States. We describe the characteristics of existing no-fault compensation systems during 2018 based on six common programme elements. No-fault compensation systems for vaccine injuries have been developed in a few high-income countries for more than 50 years. Twenty-five jurisdictions were identified with no-fault compensation programmes, of which two were recently implemented in a low- and a lower-middle-income country. The no-fault compensation programmes in most jurisdictions are implemented at the central or federal government level and are government funded. Eligibility criteria for vaccine injury compensation vary considerably across the evaluated programmes. Notably, most programmes cover injuries arising from vaccines that are registered in the country and are recommended by authorities for routine use in children, pregnant women, adults (e.g. influenza vaccines) and for special indications. A claim process is initiated once the injured party or their legal representative files for compensation with a special administrative body in most programmes. All no-fault compensation programmes reviewed require standard of proof showing a causal association between vaccination and injury. Once a final decision has been reached, claimants are compensated with either: lump-sums; amounts calculated based on medical care costs and expenses, loss of earnings or earning capacity; or monetary compensation calculated based on pain and suffering, emotional distress, permanent impairment or loss of function; or combination of those. In most jurisdictions, vaccine injury claimants have the right to seek damages either through civil litigation or from a compensation scheme but not both simultaneously. Data from this report provide an empirical basis on which global guidance for implementing such schemes could be developed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Its design reflects a deliberate policy choice to balance two core imperatives: ensuring timely and fair compensation for parties harmed by socially valuable technologies, and preserving the conditions necessary for sustainable innovation and public welfare (Yang and Reiss 2023; Mungwira et al. 2020).”
From Bridging Liability Gaps in the Age of AI: The Case for No-Fault Compensation Schemes (2025) · cites this paper as Mungwira et al. 2020
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Unlike many other countries, Australia does not have a general NFCS for vaccine injury (Mungwira, et al. 2020).”
From Ethical Principles in Legal Context: Vaccine Mandates During the COVID-19 Pandemic in Australia (2026) · cites this paper as Mungwira, et al. 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2013) · Vaccine · doi:10.1016/j.vaccine.2013.02.015 · Cited by 551
Lei, J., Balakrishnan, M. R., Gidudu, J., & ZUBER, P. L. F. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.02.012 · Cited by 162
Self-citationLooker, C., & Kelly, H. (2011) · Bulletin of the World Health Organization · doi:10.2471/blt.10.081901 · Cited by 88 · cited 10×
“The drive to implement no-fault compensation programmes in most jurisdictions increased with reports of adverse events following immunisation with diphtheria-tetanus-whole cell pertussis in the 1970s [2].”
InfluentialVaccine injury compensation programs worldwide
Evans, G. (1999) · Vaccine · doi:10.1016/s0264-410x(99)00291-1 · Cited by 76 · cited 6×
“…individuals who experience a rare vaccine-related injury due to the inherent risk of vaccination (e.g. intus-susception in an infant following vaccination with a well manufactured and administered rota-virus vaccine, or a life-threatening anaphylactic reaction following any vaccine) [1–3].”
InfluentialThe National Vaccine Injury Compensation Program
Cook, K. M., & Evans, G. (2011) · PEDIATRICS · doi:10.1542/peds.2010-1722k · Cited by 49
The Global Vaccine Safety Initiative: enhancing vaccine pharmacovigilance capacity at country level
Maure, C. G., Dodoo, A., Bonhoeffer, J., & ZUBER, P. L. F. (2014) · Bulletin of the World Health Organization · doi:10.2471/blt.14.138875 · Cited by 39
Self-citationRATIONALIZING VACCINE INJURY COMPENSATION
MELLO, M. M. (2008) · Bioethics · doi:10.1111/j.1467-8519.2007.00590.x · Cited by 34 · cited 1×
“For the injured party, usually, those with adequate resources would afford to access litigation procedures creating inequity to accessing compensation [27, 28].”
The Case for a Vaccine Injury Compensation Program for Canada
Wilson, K. R., & Keelan, J. E. (2012) · Canadian Journal of Public Health · doi:10.1007/bf03404215 · Cited by 33 · cited 1×
“Proponents of this administrative approach argue it is less adversarial, more economical, and reduces the need to allot blame whilst maximizing opportunity for those with genuine vaccine injuries to access fair compensation [2, 30].”
No-Fault Compensation Schemes for Medical Injury: A ReviewPreprint
Farrell, A., Devaney, S., & Dar, A. (2013) · SSRN Electronic Journal · doi:10.2139/ssrn.2221836 · Cited by 22
Administrative Compensation of Medical Injuries: A Hardy Perennial Blooms Again
Barringer, P. J., Studdert, D. M., Kachalia, A. B., & Mello, M. M. (2008) · Journal of Health Politics Policy and Law · doi:10.1215/03616878-2008-014 · Cited by 21
A Global Vaccine Injury Compensation System
Halabi, S., & Omer, S. B. (2017) · JAMA · doi:10.1001/jama.2016.19492 · Cited by 19 · cited 2×
“…of vaccine manufacturers from liability, sustaining vaccine supply and stabilizing vaccine prices as benefits of compensation programmes [1, 2, 6], our findings suggest that these programmes are increasingly being considered for fair compensation of injured party and maintain confidence in…”
Kim, M.-K., Lee, Y.-K., Kim, T. E., Kong, I., Yang, H., & Suh, E. S. (2017) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2017.6.2.146 · Cited by 15
Fei, L., & Peng, Z. (2017) · Medical Law Review · doi:10.1093/medlaw/fwx001 · Cited by 11
Should Australia introduce a vaccine injury compensation scheme?
Isaacs, D. (2004) · Journal of Paediatrics and Child Health · doi:10.1111/j.1440-1754.2004.00357.x · Cited by 10 · cited 1×
“This is accompanied by increasing interest for national no-fault compensation policies related to vaccine injuries [6–9].”
Mungwira, R. G., Maure, C. G., & ZUBER, P. L. F. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.06.018 · Cited by 10 · cited 3×
“This descriptive analysis of the characteristics of WHO member states with no-fault compensation programmes implemented is published elsewhere [10].”
InfluentialSelf-citationTuells, J. (2013) · Medicina Clínica · doi:10.1016/j.medcli.2013.01.043 · Cited by 9
A no‐fault compensation scheme for serious adverse events attributed to vaccination
Kelly, H. A., Looker, C., & Isaacs, D. (2011) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2011.tb03176.x · Cited by 9
National Vaccine Injury Compensation Program: Revisions to the Vaccine Injury Table. Final rule.
(2017) · PubMed · Cited by 4
[The National Vaccine Injury Compensation Program in Japan].
Ihara, T. (2011) · PubMed · Cited by 4
Litigation a Threat to Vaccine Supply?
Franklin, D. (1984) · Science News · doi:10.2307/3969230 · Cited by 1 · cited 1×
“For vaccine manufacturers, an increase in litigation cases and substantial amounts paid out in compensation led to most players exiting the market and a subsequent significant decline in vaccine supply [29].”
Research works printed but not linked: 4
- J Tuells, 2013, Reasons for an injury compensation programme for adverse vaccine-related events in Spain, Med Clin (Barc), 140, 554
- University of Toronto, 2011, Designing a No-fault Vaccine-injury Compensation Programme for Canada: Lessons Learned from an International Analysis of Programmes: Munk School of Global Affairs
- Organization WH, 2018, The Global Immunization Meeting: Successfully Navigating Transitions
- 18th International Conference of Drug Regulatoru Authorities (ICDRA) 2018 [cited 2018 18 Oct 2018]. 18th ICDRA Conference official website]. Available from: http://www.icdra2018.ie/.
Cited by
Enhancing public trust in COVID-19 vaccination: The role of governments
(2021) · OECD Policy Responses to Coronavirus (COVID-19) · doi:10.1787/eae0ec5a-en · Cited by 297
Chen, S., Yao, L., Wang, W., & Tang, S. (2022) · The Lancet Public Health · doi:10.1016/s2468-2667(22)00171-2 · Cited by 61
No-Fault Compensation for Vaccine Injury — The Other Side of Equitable Access to Covid-19 Vaccines
Halabi, S., Heinrich, A., & Omer, S. B. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2030600 · Cited by 44
D’Errico, S., Zanon, M., Concato, M., Peruch, M., Scopetti, M., Frati, P., & Fineschi, V. (2021) · Vaccines · doi:10.3390/vaccines9101116 · Cited by 24
Gorodensky, A., & Kohler, J. C. (2022) · Journal of Pharmaceutical Policy and Practice · doi:10.1186/s40545-022-00442-y · Cited by 21
“To reap compensation for vaccine-related injuries through no-fault compensation schemes, however, patients do not need to prove fault; in some jurisdictions such as the United States, patients who make a claim to a compensation scheme waive their right to bring a civil case against the vaccine manufacturer [32, 80, 81…”
Background
Metadata
- Authors
- Mungwira, R. G., Guillard, C., Saldaña, A., Okabe, N., Petousis-Harris, H., Agbenu, E., Rodewald, L., & Zuber, P. L. F.
- Affiliations
- University of Siena (IT)
- World Health Organization (CH)
- Instituto de Salud Pública de Chile (CL)
- Kawasaki City Institute for Public Health (JP)
- Chinese Center For Disease Control and Prevention (CN)
- Corresponding author
- Mungwira, Randy G.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2020-05-21
- Volume
- 15
- Issue
- 5
- Pages
- e0233334
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC7241762
- OpenAlex
- W3027414698
- Cited by
- 68
- References
- 20
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 5 · 2023: 30 · 2022: 8 · 2021: 12 · 2020: 4
- FWCI
- 3.41
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- ResearchSpace (University of Auckland) (submittedVersion, cc-by)
- Funders
- World Health Organization
- Università degli Studi di Siena
- Topics
- Social Sciences › Law › Medical Malpractice and Liability Issues
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Emergency Medicine › Intramuscular injections and effects
- Keywords
- no-fault compensation, vaccine injury, vaccine safety, claim process, standard of proof, compensation amount, earnings losses, pain and suffering, civil litigation, WHO member states
- MeSH terms
- Adult, Child, Female, Health Policy, Humans, Insurance, Liability, Male, Malpractice, National Health Programs, Pregnancy, Surveys and Questionnaires, Vaccination, Vaccines, Global Health, World Health Organization, Liability, Legal, Compensation and Redress
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.